Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 309

A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Status: Active
Location: 3 locations
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Intraperitoneal FT536 with Lymphodepleting Chemotherapy for the Treatment of Patients with Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Lurbinectedin in Combination with Paclitaxel and Bevacizumab for the Treatment of Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPI-0209 in Combination with Carboplatin for the Treatment of Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Hyperthermic Intraperitoneal Chemotherapy with Cisplatin After Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Status: Active
Location: 4 locations
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Autologous B7-H3 Chimeric Antigen Receptor T Cells for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T cells for the Treatment of Patients with Recurrent Platinum Resistant or Refractory Epithelial Ovarian Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Adagrasib in Combination with Olaparib for the Treatment of KRAS G12C Mutated Advanced Solid Tumors with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Genetically Engineered Cells (FSHCER T cells) for the Treatment of Recurrent Platinum-resistant or Platinum-refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas